{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:14:56Z","timestamp":1769116496375,"version":"3.49.0"},"reference-count":42,"publisher":"American Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the pandemic of type 2 diabetes. Here, the authors aimed to assess the performance of the most commonly used noninvasive, blood-based biomarkers for liver fibrosis (FibroTest, NAFLD fibrosis score, BARD score, and FIB-4 Index) in subjects with type 2 diabetes. Liver stiffness measurement was estimated by two-dimensional shear wave elastography. Finally, the authors assessed the diagnostic role of ActiTest and NashTest 2 in liver fibrosis in the examined population.<\/jats:p>","DOI":"10.2337\/cd21-0104","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T21:38:20Z","timestamp":1648071500000},"page":"327-338","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":5,"title":["Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes"],"prefix":"10.2337","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9361-9459","authenticated-orcid":false,"given":"Angeliki","family":"Meritsi","sequence":"first","affiliation":[{"name":"1Diabetic Center, 2nd Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Latsou","sequence":"additional","affiliation":[{"name":"2Department of Social and Educational Policy, University of Peloponnese, Corinth, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Manesis","sequence":"additional","affiliation":[{"name":"3Liver Unit, Euroclinic, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias","family":"Gatos","sequence":"additional","affiliation":[{"name":"4Diagnostic Echotomography, SA, Kifissia, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Theotokas","sequence":"additional","affiliation":[{"name":"4Diagnostic Echotomography, SA, Kifissia, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavlos","family":"Zoumpoulis","sequence":"additional","affiliation":[{"name":"4Diagnostic Echotomography, SA, Kifissia, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stamatia","family":"Rapti","sequence":"additional","affiliation":[{"name":"5Laboratory of Molecular Genetics, Biomedicine, SA, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eustathios","family":"Tsitsopoulos","sequence":"additional","affiliation":[{"name":"5Laboratory of Molecular Genetics, Biomedicine, SA, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hariklia","family":"Moshoyianni","sequence":"additional","affiliation":[{"name":"6Biomedicine, SA, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spilios","family":"Manolakopoulos","sequence":"additional","affiliation":[{"name":"7Liver and Gastrointestinal Unit, 2nd Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Pektasides","sequence":"additional","affiliation":[{"name":"82nd Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Thanopoulou","sequence":"additional","affiliation":[{"name":"1Diabetic Center, 2nd Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022071518582561500_B1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"2022071518582561500_B2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"2022071518582561500_B3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"key":"2022071518582561500_B4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2337\/dc10-2229","article-title":"Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study","volume":"34","author":"Williamson","year":"2011","journal-title":"Diabetes Care"},{"key":"2022071518582561500_B5","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","article-title":"Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma","volume":"126","author":"El-Serag","year":"2004","journal-title":"Gastroenterology"},{"key":"2022071518582561500_B6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: a stage-based approach","volume":"13","author":"Rinella","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022071518582561500_B7","doi-asserted-by":"crossref","first-page":"W20","DOI":"10.2214\/AJR.19.21267","article-title":"Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease","volume":"214","author":"Furlan","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"2022071518582561500_B8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH: current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022071518582561500_B9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-230X-6-34","article-title":"Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease","volume":"6","author":"Poynard","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"2022071518582561500_B10","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"2022071518582561500_B11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajg.2017.05.005","article-title":"APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis: systematic review and meta-analysis","volume":"18","author":"El Serafy","year":"2017","journal-title":"Arab J Gastroenterol"},{"key":"2022071518582561500_B12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J Hepatol"},{"key":"2022071518582561500_B13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2010.06.028","article-title":"Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease","volume":"54","author":"Ruffillo","year":"2011","journal-title":"J Hepatol"},{"key":"2022071518582561500_B14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.12647","article-title":"Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study","volume":"46","author":"Sun","year":"2016","journal-title":"Hepatol Res"},{"key":"2022071518582561500_B15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/jmri.25006","article-title":"Accuracy and the effect of possible subject-based confounders of magnitude-based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference","volume":"43","author":"Heba","year":"2016","journal-title":"J Magn Reson Imaging"},{"key":"2022071518582561500_B16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/apt.13405","article-title":"Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE","volume":"43","author":"Doycheva","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071518582561500_B17","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1148\/radiol.2015150619","article-title":"Elastography assessment of liver fibrosis: Society of Radiologists in Ultrasound consensus conference statement","volume":"276","author":"Barr","year":"2015","journal-title":"Radiology"},{"key":"2022071518582561500_B18","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.ultrasmedbio.2018.07.008","article-title":"Liver ultrasound elastography: an update to the World Federation for Ultrasound in Medicine and Biology guidelines and recommendations","volume":"44","author":"Ferraioli","year":"2018","journal-title":"Ultrasound Med Biol"},{"key":"2022071518582561500_B19","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1055\/a-0586-1107","article-title":"The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: update 2017 (long version)","volume":"39","author":"Sidhu","year":"2018","journal-title":"Ultraschall Med"},{"key":"2022071518582561500_B20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2337\/dc10-1991","article-title":"Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study","volume":"34","author":"Bae","year":"2011","journal-title":"Diabetes Care"},{"key":"2022071518582561500_B21","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/ajg.2013.349","article-title":"Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population","volume":"108","author":"Chang","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2022071518582561500_B22","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/hep.26183","article-title":"Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study","volume":"57","author":"Park","year":"2013","journal-title":"Hepatology"},{"key":"2022071518582561500_B23","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.2337\/dc07-0792","article-title":"Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men","volume":"30","author":"Shibata","year":"2007","journal-title":"Diabetes Care"},{"key":"2022071518582561500_B24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11892-007-0029-z","article-title":"NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes","volume":"7","author":"Bugianesi","year":"2007","journal-title":"Curr Diab Rep"},{"key":"2022071518582561500_B25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.27981","article-title":"Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam Study","volume":"63","author":"Koehler","year":"2016","journal-title":"Hepatology"},{"key":"2022071518582561500_B26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.25772","article-title":"Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis","volume":"56","author":"Loomba","year":"2012","journal-title":"Hepatology"},{"key":"2022071518582561500_B27","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ijc.26165","article-title":"Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies","volume":"130","author":"Wang","year":"2012","journal-title":"Int J Cancer"},{"key":"2022071518582561500_B28","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/0016-5085(90)91167-5","article-title":"A 21-year experience with major hemorrhage after percutaneous liver biopsy","volume":"99","author":"McGill","year":"1990","journal-title":"Gastroenterology"},{"key":"2022071518582561500_B29","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"2022071518582561500_B30","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022071518582561500_B31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systemic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"2022071518582561500_B32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.22576","article-title":"Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease","volume":"49","author":"Naveau","year":"2009","journal-title":"Hepatology"},{"key":"2022071518582561500_B33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0168-8278(03)00171-5","article-title":"Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B","volume":"39","author":"Myers","year":"2003","journal-title":"J Hepatol"},{"key":"2022071518582561500_B34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-230X-6-6","article-title":"Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"6","author":"Ratziu","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"2022071518582561500_B35","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/hep.510300604","article-title":"Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis","volume":"30","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"key":"2022071518582561500_B36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/jim-2018-000864","article-title":"Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus","volume":"67","author":"Bril","year":"2019","journal-title":"J Investig Med"},{"key":"2022071518582561500_B37","article-title":"High prevalence of NAFLD in patients with obesity and type 2 diabetes [Abstract]","author":"Repetto"},{"key":"2022071518582561500_B38","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/jcm9041032","article-title":"Screening for liver fibrosis and steatosis in a large cohort of patients with type 2 diabetes using vibration controlled attenuation parameter in a single-centre real-life experience","volume":"9","author":"Sporea","year":"2020","journal-title":"J Clin Med"},{"key":"2022071518582561500_B39","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jhep.2013.10.017","article-title":"Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study","volume":"60","author":"Morling","year":"2014","journal-title":"J Hepatol"},{"key":"2022071518582561500_B40","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.diabet.2019.11.004","article-title":"Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes","volume":"46","author":"Mantovani","year":"2020","journal-title":"Diabetes Metab"},{"key":"2022071518582561500_B41","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/jgh.14577","article-title":"Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography","volume":"34","author":"Lai","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"2022071518582561500_B42","doi-asserted-by":"crossref","first-page":"e0236977","DOI":"10.1371\/journal.pone.0236977","article-title":"Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus","volume":"15","author":"Chen","year":"2020","journal-title":"PLoS One"}],"container-title":["Clinical Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/clinical\/article-pdf\/40\/3\/327\/685504\/diaclincd210104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/clinical\/article-pdf\/40\/3\/327\/685504\/diaclincd210104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T05:49:54Z","timestamp":1700372994000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/clinical\/article\/40\/3\/327\/144850\/Noninvasive-Blood-Based-Biomarkers-as-Screening"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/cd21-0104","relation":{},"ISSN":["0891-8929","1945-4953"],"issn-type":[{"value":"0891-8929","type":"print"},{"value":"1945-4953","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}